A Phase 1, Randomized, Open-Label, Crossover Study to Investigate the Relative Bioavailability of LY4065967 Formulations in Healthy Participants
Eli Lilly and Company
Summary
The main purpose of this study is to compare 3 different forms of LY4065967 - a tablet and 2 types of capsule - to see how much and how quickly each gets into the bloodstream after it is swallowed, and to check for any side effects. For each participant, the study will last about 7 weeks and will include 3 stays in the Clinical Research Unit (CRU). Each stay will last 3 nights.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. * Have clinical laboratory test results within normal reference range for the population or investigative site. * Have an electrocardiogram (ECG) at screening considered to be within acceptable limits by the investigator. * Have a body mass index within the range 18.0 to 35.0 kilograms per square meter (kg/m²) (inclusive). * Individuals assigned male at birth (AMAB) or assigned female at birth (AFAB) may participate in this trial. * Have venous a…
Interventions
- DrugLY4065967 Tablet
Administered orally
- DrugLY4065967 Formulated Capsule
Administered orally
- DrugLY4065967 Capsule
Administered orally
Locations (2)
- Fortrea Clinical Research UnitDaytona Beach, Florida
- Fortrea Clinical Research UnitDallas, Texas